Jackson Walker advised South Texas Accelerated Research Therapeutics (START), the nation’s largest Phase I cancer clinical trial research company, in forming a strategic partnership with global private equity firm Warburg Pincus. Through this transaction, Warburg Pincus has acquired a majority interest in START, providing the company with significant new investment to accelerate clinical operations around the world and fuel future expansion.
“This partnership with Warburg Pincus is a transformative moment for START,” said partner Patrick Tobin, who led the Jackson Walker team. “Warburg Pincus’s global network will help expand START’s reach and make a positive impact on the lives of even more cancer patients. It’s an honor to have assisted in this important deal.”
Founded in 2007, and represented by Jackson Walker since inception, START is a world-wide leader in Phase I cancer clinical research, with facilities strategically located in San Antonio, Texas; Grand Rapids, Michigan; Salt Lake City, Utah; and international sites in Madrid and Barcelona, Spain; Lisbon, Portugal; and Dublin, Ireland.
The Jackson Walker team included Patrick Tobin (corporate law), Edgar “Jed” Morrison (healthcare law), Shari Mao (corporate law), Ron Kerridge (tax), William “Billy” McDonough (corporate law), Brian Pettis (corporate law), and Daniel Maldonado (corporate law).
More information about the transaction can be found in the San Antonio Business Journal article “Breaking: SA cancer research company gets new majority investor and CEO.”
Meet JW
Since Jackson Walker’s founding in 1887, our attorneys have represented some of the most influential companies and business leaders in the world. Today, we remain firmly rooted in Texas while serving clients around the globe. With more than 500 attorneys across six offices, we are the largest Texas firm and have been recognized by Law360 as a “Texas Powerhouse” and an “elite law firm” that regularly provides counsel to industry-leading clients on highly complex transactions ranging from millions to billions. To explore the Firm’s experience in mergers, acquisitions, dispositions, joint ventures, and other strategic alliances, visit the Corporate & Securities practice page.
